CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Gallium Ga 68-DOTATATE +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03448458
NCT03448458Phase 2Completed
CompareCT.gov

Molecular Imaging With Ga-68 DOTATATE PET to Investigate Neuroendocrine Differentiation in Prostate Cancer Patients

Emory University·interventional·Posted Feb 28, 2018·Updated Jul 17, 2025

In Brief

A Phase 2 clinical trial evaluating CT (Computed Tomography), Gallium Ga 68-DOTATATE, and 1 other intervention for Castration-Resistant Prostate Carcinoma and 2 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This pilot clinical trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in treating patients with castration resistant prostate cancer that has spread to other placed in the body. Gallium Ga 68-DOTATATE PET/CT may help doctors to identify those patients with early neuroendocrine transdifferentiation and who are at greater risk for poor outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 28, 2018
Enrollment StartFeb 22, 2018
Primary CompletionFeb 6, 2023
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.3 years ago

Interventions

CT (Computed Tomography)procedure

Undergo PET/CT

Gallium Ga 68-DOTATATEdrug

Given IV

Positron Emission Tomographyprocedure

Undergo PET/CT